New pharma products to add $100bn of value to market by 2016

Kalorama's latest report has analysed the late-stage R&D pipelines of 50 leading pharmaceutical companies.

The top 50 pharmaceutical companies are currently working on around 724 development projects and will add billions in value to the market over the next few years, a report has forecast.

Kalorama Information's latest research looked at the late-stage R&D pipelines of the 50 leading pharmaceutical companies, which produce the majority of industry revenues, to 2016.

The research firm predicts that new products will add around $100 billion to the pharmaceutical market during that time, assuming average approval ratios are maintained.

A "good number" of these new products will be biopharmaceuticals, with the highest proportion of newly approved drugs likely to be in the field of oncology.

Report author Melissa Elder, an analyst at Kalorama Information, said: "Drugs in the oncology segment are expected to make a significant impact on current markets.

"New entrants will in